← Eichor
Study identifier: NCT07093346 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Condition: Nonalcoholic Fatty Liver Disease · Nonalcoholic Fatty Liver Disease (NAFLD) · MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease  ·  Sponsor: University of Nottingham

PhaseNA
Planned participants45
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is: -How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD? Researchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota. Participants will: * Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control) * Provide stool and fasting blood samples before and after the intervention * Undergo anthropometric measurements (weight, height, waist/hip ratio, and blood pressure) * Complete a case report form (CRF) including demographics and health/medical history * Undergo a FibroScan™ to assess liver health * (Optional) Participate in MRI scans to evaluate gut permeability

This description comes directly from the study's public registry record.

Talk to the study team

Noor K Al-Tameemi, PhD student candidate  ·  0044 01158231149  ·  noorkifahabdulhussein.al-tameemi@nottingham.ac.uk

Guruprasad P Aithal, Professor  ·  0044 01158231149  ·  guru.aithal@nottingham.ac.uk

Always discuss trial participation with your own doctor first.

Locations (3)

Sir Peter Mansfield Imaging Centre, University of NottinghamNottingham, United KingdomRecruiting
Nottingham Clinical Research Facility at Nottingham University Hospitals NHS TrustNottingham, United KingdomRecruiting
University of NottinghamNottingham, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07093346